Breast Cancer - Data Show Synergistic Activity Of Telomerase Inhibitor Drug And Trastuzumab On Inhibiting Cell Growth
Oct 27th 2008Drug InformationBreast Cancer
Geron Corporation (Nasdaq:GERN) today announced the publication of preclinical data demonstrating that its telomerase inhibitor drug, GRN163L, significantly boosts the effects of trastuzumab (Herceptin?) against HER2-positive breast cancer cells and restores sensitivity to trastuzumab in trastuzumab resistant tumor cells. The research published online yesterday in Breast Cancer Research and Treatment was conducted by Dr.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
